書籍詳細

PART1. プロトンポンプ阻害薬の開発の歴史をみる

P.8 掲載の参考文献

• 1) Brandstrom A, Lindberg P, Junggren U:Structure activity relationships of substituted benzimidazoles. Scand J Gastroenterol 20 (suppl 108):s 15-s 22, 1985

• 2) Lindberg B Brandstrom A, Wallmark B et al:Omeprazole:the first proton pump inhibitor. Med Res Rev 10:1-54, 1990

• 3) Helander HF Ramsay CH, Regardh CG:Localization of omeprazole and metabolites in the mouse. Scand J Gastroenterol 20 (suppl 108):s 95-s 104, 1985

• 4) Shin JM, Cho YM, Sachs G:Chemistry of covalent inhibition of the gastric H+, K+-ATPase by proton pump inhibitors. J Am Chem Soc 126:7800-7811, 2004
  pubmed

• 5) Lind T, Cederberg C, Ekenved G et al:Effect of omeprazole-a gastric proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut 24:270-276, 1983
  pubmed

PART2. 消化性潰瘍治療におけるプロトンポンプ阻害薬のインパクトを探る

P.15 掲載の参考文献

• 1) 矢花剛, 小林壮光, 柴田香織:消化性潰瘍治療薬の史的変遷. 消化性潰瘍治療のすべて, 浅香正博, 千葉勉編, 先端医学社, 東京, 1997, pp.30-39

• 2) Ikeda S, Tamamuro T, Hamashima C et al:Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan. Aliment Pharmacol Ther 15:1777-1785, 2001
  pubmed

• 3) Richardson CT:Effect of H2-receptor antagonists on gastric acid secretion and serum gastrin concentration:a review. Gastroenterology 74:366-370, 1978
  pubmed

• 4) Isenberg JI, Peterson WL, Elashoff JD et al:Healing of benign gastric ulcer with lowdose antacid or cimetidine. a double-blind, randomized, placebo-controlled trial. N Engl J Med 308:1319-1324, 1983
  pubmed

• 5) Prichard PJ, Yeomans ND, Mihaly GW et al:Omeprazole:a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 88:64-69, 1985
  pubmed

• 6) Wallmark B, Lorentzon P, Larsson H:The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro. Scand/Gastroenterol 20 (suppl 108):37-51, 1985

• 7) 西元寺克禮:維持療法. 消化性潰瘍, 浅香正博編, 最新医学社, 東京, 2002, pp.184-191

• 8) Strum WB:Prevention of duodenal ulcer recurrence. Ann Intern Med 105:757-761, 1986
  pubmed

• 9) Warren JR, Marshall BJ:Unidentified curved bacilli on gastric epithelium in active gastritis (letter). Lancet i:1273, 1983

• 10) Van der Hulst RW, Rauws EA, Koycu B et al:Prevention of ulcer recurrence after eradication of Helicobacter pylori:aprospective long-term follow-up study. Gastroenterology 113:1082-1086, 1997

• 11) Asaka M, Kato M, Sugiyama T et al:Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 38:339-347, 2003
  pubmed

• 12) Graham DY, Agrawal NM, Roth SH:Prevention of NSAID-induced gastric ulcer with misoprostol:multicentre, double-blind, placebo-controlled trial. Lancet ii:1277-1280, 1988

PART3. 21世紀におけるプロトンポンプ阻害薬の臨床的意義を探る

P.28 掲載の参考文献

• 1) 高橋信一, 伊藤武, 斎藤昌三:除菌療法の実際. ヘリコバクター・ピロリとその除菌法, 寺野彰, 高橋信一編, 南江堂, 東京, 1999, pp.85-95

• 2) 大蔵隆一, 佐藤信紘:プロトンポンプ阻害薬の抗菌作用と臨床的有用性. プロトンポンプ阻害薬のすべて, 浅香正博, 千葉勉編, 先端医学社, 東京, 2002, pp.79-82

• 3) Chiba N, Rao BV, Rademaker JW et al:Meta-analysis of the efficacy of antibiotics therapy in eradicating Helicobacter pylori. Am J Gastroenterol 87:1716-1727, 1992
  pubmed

• 4) Martin DF, Hollanders D, May SJ et al:Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet iii:7-10, 1981
  pubmed

• 5) 菅野健太郎:除菌治療におけるPPI製剤の役割と意義. 日臨 60:627-631, 2002
  Medical*Online

• 6) 日本消化器病学会Helicobacter pylori治験検討委員会:Helicobacter Pylori治験ガイドライン資料, 竹本忠良編, 1995

• 7) Lind T, Veldhuyzen van Zanten S, Unge P et al:Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials. Helicobacter 1:138-144, 1996
  pubmed

• 8) Lind T, Megraud E Unge P et al:The MACH 2 study:Role of Omeprazole in Eradication of Helicobacter pylori with 1-Week Triple Therapies. Gastroenterology 116:248-253, 1999

• 9) Malfertheiner P, Bayerdorffer E, Diete U et al:The GU-MACH study:the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 13:703-712, 1999

• 10) Veldhuyzen van Zanten S, Bradette M, Farley A et al:The DU-MACH study:eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 13:289-295, 1999

• 11) 日本ヘリコバクター学会ガイドライン作成委員会:H. Pylori感染の診断と治療のガイドライン. 日本ヘリコバクター学会誌 2:2-12, 2000
  Medical*Online

• 12) 日本ヘリコバクター学会ガイドライン作成委員会:H. Pylori感染の診断と治療のガイドライン 2003年改訂版. 日本ヘリコバクター学会誌 7:253-265, 2003

P.38 掲載の参考文献

• 1) 高久史麿:医療技術評価推進検討会報告書;わかりやすいEBM講座, 厚生省健康政策局研究開発振興課医療技術情報推進室監修, 厚生科学研究所, 東京, 2000, pp.8-28

• 2) EBMに基づく胃潰瘍診療ガイドライン:科学的根拠 (evidence) に基づく胃潰瘍診療ガイドラインの策定に関する研究班編, じほう, 東京, 2003, pp.55-106

• 3) Donnellan C, Sharma N, Preston C et al:Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (review). Cochrane Database Syst Rev 18:CD003245, 2005

• 4) Soga T, Matsuura M, Kodama Y et al:Is proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis? J Gastroenterol 34:435-440, 1999
  pubmed

• 5) Di Mario F, Battaglia G, Leandro G et al:Short-term treatment of gastric ulcer:a meta-analytical evaluation of blind trials. Dig Dis Sci 41:1108-1131, 1996
  pubmed

• 6) Eriksson S, Langstrom G, Rikner L et al:Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis:ametaanalysis. Eur J Gastroenterol Hepatol 7:467-475, 1995

• 7) Poynard T, Lemaire m, Agostini H:Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 7:661 665, 1995
  pubmed

• 8) Isomoto H, Inoue K, Furusu H et al:Lafutidine, a novel histamine H2-receptor antagonist, vs. lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Helicobacter 8:111-119, 2003
  pubmed

• 9) Graham DY, Hammoud E El-Zimaity HMT et al:Meta-analysis:proton pump inhibitor or H2-receptor antagonist for Helicobacter Pylori eradication. Aliment Pharmacol Ther 17:1229-1236, 2003
  pubmed

P.46 掲載の参考文献

• 1) Heudebert GR, Centor RM, Klapow JC et al:What is heartburn worth?Acost-utility analysis of management strategies. J Gen Intern Med 15:175-182, 2000

• 2) Gerson LB, Robbins AS, Garber A et al:Acost-effectiveness analysis of prescribing strategies in the management of gastroesophageal refiux disease. Am J Gastroenterol 95:395-407, 2000

• 3) Jonsson B, Wahlqvist P:Management of nonsteroidal anti-inflammatory drug-associated lesions:acost-effectiveness perspective. Am J Med 104:S81-S88, 1998

• 4) 羽生泰樹, 清田啓介, 井口秀人:消化性潰瘍治療におけるnew triple therapy と dual therapy-除菌率と費用効果の観点から-. 日臨 57:135-139, 1999

• 5) Ikeda S, Tamamuro T, Hamashima T et al:Evaluation of the cost-effectiveness of Helicobacter Pylori eradication triple therapy vs conventional therapy for ulcers in Japan. Aliment Pharmacol Ther 15:1777-1785, 2001

P.54 掲載の参考文献

• 1) 千葉寛:薬物代謝に関しての薬物間相互作用の基礎知識. 治療 76:2214-2220, 1994
  Medical*Online

• 2) Ishizaki T, Horai Y:Review article:cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther 13 (suppl 3):27-36, 1999

• 3) Horai Y, Ishizaki T:Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism. Ration Drug Ther 22:1-8, 1988
  pubmed

• 4) Kubota T, Chiba K, Ishizaki T:Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661-666, 1996

• 5) Sohn DR, Kusaka M, Ishizaki T et al:Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 52:160-169, 1992

• 6) Bertilsson L, Lou YQ, Du YL et al:Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and Smephenytoin. Clin Pharmacol Ther 51:388-397, 1992
  pubmed

• 7) Wedlund PJ, Aslanian WS, McAllister CB et al:Mephenytoin hydroxylation deficiency in Caucasians:frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36:773-780, 1984
  pubmed

• 8) Jacqz E, Dulac H Mathieu H:Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35:167-171, 1988
  pubmed

• 9) Sanz EJ, Villen T, Alm C et al:S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45:495-499, 1989

• 10) Kupfer A, Preisig R:Pharmacogenetics of mephenytoin:a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753-759, 1984
  pubmed

• 11) Ando T, Kato H, Sugimoto N et al:Acomparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. 1) ig 1) is Sci 50:1625-1631, 2005

• 12) Ybshida N, Ybshikawa T, Tanaka Y et al:A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 14 (suppl 1):74-81, 2000

• 13) Ichikawa H, Ybshida N, Takagi T et al:Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol 10:2814-2817, 2004

• 14) Kuroda M, Ybshida N, Ichikawa et al:Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med:2005 (in press)

• 15) Ybshida N, Uchiyama K, Kuroda M et al:Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol 39:816-822, 2004

PART4. 薬理学からみたプロトンポンプ阻害薬の特徴をみる

P.66 掲載の参考文献

• 1) Soll AH, Grossman MI:The interaction of stimulants on the function of isolated canine parietal cells. Philos Trans R Soc Lond B Biol Sci 296:5-15, 1981
  pubmed

• 2) 屋嘉比康治, 中村孝司:消化性潰瘍治療の基本戦略とオメプラゾールII. Pharma Medica 11:167-173, 1993

• 3) Walan A, Bader JP, Classen M et al:Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 320:69-75, 1989
  pubmed

• 4) Peghini PL, Katz PO, Bracy NA et al:Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763-767, 1998
  pubmed

• 5) 古田隆久:プロトンポンプ阻害薬:EM・PM からみた有効性と使い方. H. Pylori除菌時代の消化性潰瘍の治療, 中村孝司編, 日本メディカルセンター, 東京, 2000, pp.189-194

• 6) Solcia E, Villani L, Fiocca R et al:Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 29 (suppl 201):S28-S34, 1994

• 7) Logan RPH, Walker MM, Misiewicz JJ et al:Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36:12-16, 1995

• 8) Kuipers EJ, Utyterlinde AM, Pena AS et al:Increase of Helicobacter pylori-associated corpus gastritis during acid supressive therapy:implications for long-term safety. Am J Gastroenterol 90:1401-1406, 1995

• 9) Uemura N, Oomoto Y, Mukai T et al:Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients. Aliment Pharmacol Ther 11:793-800, 1997
  pubmed

• 10) Kuipers EJ, Lundell L, Kliinkenberg-Knol EC et al:Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334:1018-1022, 1996
  pubmed

• 11) Eissele R, Brunner G, Simon B et al:Gastric mucosa during treatment with lansoprazole:Helicobacter Pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterol 112:707-717, 1997

• 12) Lundell L, Miettinen P, Myrvold HE et al:Lack of effecr of acid suppression therapy on gastric atrophy Gastroenterol 117:319-326, 1999

• 13) Meining A, Kiel G, Stolte M:Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Alim Pharmacol Ther 12:735-740, 1998

• 14) Genta RM:Helicobacter pylori, Inflammation, mucosal damage, and apoptosis:pathogenesis and definition of gastric atrophy. Gastroenterology 113 (suppl 6):S51-S55, 1997

• 15) Robinson M:Review article:current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 13 (suppl 5):S5-SIO, 1999

P.73 掲載の参考文献

• 1) Suzuki M, Mori M, Miura S et al:Omeprazole attenuates oxygerderived free radical production from human neutrophils. Free Radic Biol Med 21:727-731, 1996
  pubmed

• 2) Suzuld M, Nakamura M, Mori M et al:Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol 20 (suppl 2):s93-s96, 1995

• 3) Wandall JH:Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation and translocation of cytochrome b-245. Gut 33:617-621, 1992
  pubmed

• 4) Yoshida N, Ybshikawa T, Tanaka Y et al:A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 14 (suppl 1):S74-S81, 2000

• 5) Natale G, Lazzeri G, Lubrano V et al:Mechanisms of gastroprotection by lansoprazole pretreatment against experimentally induced injury in rats:role of mucosal oxidative damage and sulfhydryl compounds. Toxicol Appl Pharmacol 195:62-72, 2004
  pubmed

• 6) Blandizzi C, Fornai M, Colucci R et al:Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. VVorld J Gastroenterol 11:4052-4060, 2005

• 7) Ohara T, Morishita T, Suzuki H et al:Usefulness of proton pump inhibitor (PPI) maintenance therapy fbr patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori:pathophysiological characteristics of H. Pylori-negative recurrent ulcer scars and beyond acid suppression by PPI. Hepatogastroenterology 51:338-342, 2004

• 8) Suzuki M, Suzuki H, Kitahora T et al:Helicobacter pylori-eradication therapy decreases the level of neutrophil-derived oxidants in the ulcerous Inucosa of the human stomach:relationship between ulcer stage and mucosal oxidant level. Dig Endosc 15:270-274, 2003

• 9) Suzuki M, Suzuki H, Kitahora T et al:Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis. Aliment Pharmacol Ther 16:159-165, 2002
  pubmed

• 10) Suzuki M, Tanaka S, Suzuki K et al:Gastric mucosal oxidative stress is influenced by bacterial intensity of H. pylori and acidity of the stomach-quantitative analysis of bacterial load and mucosal chemiluminescence-. (投稿中)

• 11) Skoczylas T, Sarosiek I, Sostarich S et al:Significant enhancement of gastric mucin content after rabeprazole administration:its potential clinical significance in acid-related disorders. Dig Dis Sci 48:322-328, 2003
  pubmed

• 12) Suzuki H, Masaoka T, Minegishi Y et al:Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen-activated protein kinase. Wound Repair Regen 12:93-99, 2004
  pubmed

• 13) Akimoto M, Hashimoto H, Shigemoto M et al:Effects of antisecretory agents on angiogenesis during healing of gastric ulcers. J Gastroenterol 40:685-689, 2005
  pubmed

• 14) Hritz I, Herszenyi L, Molnar B et al:Long-term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression.

P.83 掲載の参考文献

• 1) Marshall BJ, Warren JR:Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet i:1311-1315, 1984
  pubmed

• 2) Iwahi T, Satoh H, Nakao M et al:Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob A, gents Chemother 35:490-496, 1991

• 3) McNulty CAM:In:Treatment of Campylobacter pylori in gastritis and peptic ulcer disease, ed. by Blaser MJ, Igaku-shoin, 1989, pp. 195-207

• 4) Nagata K, Satoh H, Iwahi T et al:Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori:unique action selective for H. pylori cells. Antimicrob Agents Chemotber 37:769-774, 1993
  pubmed

• 5) 大蔵隆一, 佐藤信紘:プロトンポンプ阻害薬の抗菌作用と臨床的有用性. プロトンポンプ阻害薬のすべて, 浅香正博, 千葉勉編, 先端医学社, 東京, 2002, pp.79-82

• 6) 小林寅哲, 雑賀威, 村岡宏江ほか:Helicobacter pyloriに対する Clarithromycin の breakpoint と 23SrRNA 遺伝子のpoint mutation の相関について. 日化療会誌 49:236-240, 2001

• 7) 那須勝, 西野武志, 東健ほか:Helicobacter pylori 除菌療法における Clarithromycin および amoxicillin のブレイクポイント制定に関する報告書. 日化療会誌 48:561-567, 2000

• 8) Mine T, Yasuda H, Akimoto K et al:The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody J Clin Gastroenterol 20:S75-S78, 1995
  pubmed

• 9) Chey WD, Spybrook M, Carpenter S et al:Prolonged effect of omeprazole on the 14Curea breath test. Am J Gastroenterol 9:89-92, 1996

• 10) EL-Nujumi A, Hilditch TE, William C et al:Current on recent proton pump innibitor thelapy maehedly impairs the accuracy of the [14C] uiea beath test. Eur J Castroenterol 10:759-764, 1998

• 11) Laine L, Estrada R, Trujillo M et al:Effect of proton pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 129:547-550, 1998

• 12) Hamlet A, Stage L, Lonroth H et al:Anovel tablet-based 13C-urea breath test for Helicobacter pylori with enhanced performance during acid suppression therapy Scand J Gastroenterol 34:367-374, 1999

• 13) Savarino V, Bisso G, Pivari M et al:Effect of gestric acid suppression on 13C-urea breath test:comparison of ranitidine with omeprazole. Aliment Pharma Ther 14:291-297, 2000

P.94 掲載の参考文献

• 1) Wolfe MM, Sachs G:Acid suppression:optimizing therapy for gastroduodenal ulcer healing, gastroesophageal refiux disease, and stress-related erosive syndrome. Gastroenterology 118 (2 suppl 1):S9-S31, 2000

• 2) Lindberg P, Nordberg P, Alminger T et al:The mechanism of action of the gastric acid secretion inhibitor omeprazole.J Med Chem 29:1327-1329, 1986
  pubmed

• 3) Sachs G:Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 13 (suppl 1):S35-S41, 2001

• 4) Kromer W Kruger U, Huber R et al:Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 56:57-70, 1998
  pubmed

• 5) Ishizaki T, Horai Y:Review article:cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther 13 (suppl 3):27-36, 1999

• 6) Delhotal-Landes B, Flouvat B, Duchier J et al:Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 45:367-371, 1993
  pubmed

• 7) Stedman CA, Barclay ML:Review article:comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacot Ther 14:963-978, 2000
  pubmed

• 8) Lind T, Cederberg C, Ekenved G et al:Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. Gut 24:270-276, 1983
  pubmed

• 9) Andersson T, Andren K, Cederberg C et al:Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 29:557-563, 1990
  pubmed

• 10) Landes BD, Petite JP, Flouvat B:Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 28:458-470, 1995
  pubmed

• 11) Fuhr U, Jetter A:Rabeprazole:pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 57:595-601, 2002
  pubmed

• 12) Saitoh T, Fukushima Y, Otsuka H et al:Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 16:1811-1817, 2002
  pubmed

• 13) Modlin IM, Sachs G:In:Acid related diseases:Biology and treatment. Schnetztor-Verlag GmbH D-Konstanz, 1998, p. 93

• 14) Furuta T, Shirai N, Xiao F et al:Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484-492, 2001
  pubmed

• 15) Shirai N, Furuta T, Moriyama Y et al:Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937, 2001

• 16) Furuta T, Shirai N, Watanabe F et al:Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453-460, 2002
  pubmed

• 17) Kawamura M, Ohara S, Koike T et al:The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 17:965-973, 2003
  pubmed

• 18) Furuta T, Shirai N Takashima M et al:Effect of genotypic differences in CYP2C190n cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69:158-168, 2001
  pubmed

• 19) Peghini PL, Katz PO, Bracy NA et al:Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763-767, 1998
  pubmed

• 20) Fbuad YM, Katz PO, Castell DO:Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 13:1467-1471, 1999

PART5. プロトンポンプ阻害薬を用いた臨床応用の実際をみる 投与量,投与期間などを含め

P.105 掲載の参考文献

• 1) Collen M, Sheridan M:Gastric ulcers differ from duodenal ulcers:evaluation of basal acid output. Dig Dis Sci 38:2281-2286, 1993
  pubmed

• 2) el-Omar E, Penman I, Dorrian CA et al:Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer[see comments]. Gut 34:1060-1065, 1993

• 3) Harrison A, Isenberg JI, Schapira M et al:Most patients with active symptomatic duodenal ulcers fail to develop ulcer-type pain in response to gastroduodenal acidification. J Clin Gastroenterol 4:105-108, 1982
  pubmed

• 4) Kuwayama H:Sucralfate and cell proliferation, Plenum Press, New York, 1995

• 5) Lind T, Megraud E Unge P et al:The MACH2 study:role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies[see comments]. Gastroenterology 116:248-253, 1999

• 6) Peterson WL:The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 11 (suppl 1):S21-S25, 199

• 7) Pipkin GA, Williamson R, Wbod JR:Review article:one-week clarithromycin triple therapy regimens for eradication of, Helicobacter pylori [see comments]. Aliment Pharmacol Ther 12:823-837, 1998

• 8) 桑山肇:酸関連疾患における治療の進歩. 消臨 3:10-15, 2000

• 9) Lee A, Fox J, Hazell S:Pathogenicity of Helicobacter pylori:aperspective. Infect Immun 61:1601-1610, 1993

• 10) Weil J, Bell GD, Powell K et al:Omeprazole and Helicobacter pylori:temporary suppression rather than true eradication. Aliment Pharmacol Ther 5:309-313, 1991
  pubmed

• 11) McGowan CC, Cover TL, Blaser MJ:Helicobacter pylori and gastric acid:biological and therapeutic implications[see comments]. Gastroenterology 110:926-938, 1996

• 12) Nagata K, Satoh H, Iwahi T et al:Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter Pylori:unique action selective for H. Pylori cells. Antim icrob Agfents Chemother 37:769-774, 1993

• 13) Nagata K, Takagi E, Tsuda M et al:Inhibitory action of lansoprazole and its analogs against Helicobacter Pylori:inhibition of growth is not related to inhibition of urease. Antimicrob A, gents Chemother 39:567-570, 1995
  pubmed

• 14) Park JB, Imamura L, Kobashi K:Kinetic studies of, Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 19:182-187, 1996

• 15) Tsuchiya M, Imamura L, Park JB et al:Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 18:1053-1056, 1995
  pubmed

• 16) Mauch E Bode G, Malfertheiner P:Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors [letter]. Am J Gastroenterol 88:1801-1802, 1993

• 17) Kuipers EJ, Lundell L, Klinkenberg Knol EC et al:Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication [see comments]. N Engl J Med 334:1018-1022, 1996
  pubmed

• 18) Eissele R, Brunner G, Simon B et al:Gastric mucosa during treatment with lansoprazole:Helicobacter pylori is a risk factor for argyrophil cell hyperplasia [comment] [see comments]. Gastroenterology 112:707-717, 1997

• 19) Freston JW:Long-term acid control and proton pump inhibitors:interactions and safety issues in perspective. Am J Gastroenterol 92 (suppl 4):51S-55S; discussion 55S-57S, 1997

• 20) Lundell L, Miettinen P, Myrvold HE et al:Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 117:319-326, 1999

P.114 掲載の参考文献

• 1) EBM に基づく胃潰瘍診療ガイドライン:科学的根拠 (evidence) に基づく胃潰瘍診療ガイドラインの策定に関する研究班編, じほう, 東京, 2003

• 2) 千葉勉:胃・十二指腸潰瘍の基礎・臨床研究・今後の展望. 日臨 62:429-434, 2004
  Medical*Online

• 3) 金丸光隆, 中島光好, 梶保徳明ほか:プロトンポンプ阻害剤 Omeprazoleの胃液抑制作用-健康成人での基礎分泌および刺激分泌抑制作用について-. 臨医薬 5:13-28, 1989

• 4) 三好秋馬, 中島光好, 谷内昭ほか:胃潰瘍, 十二指腸潰瘍におけるOmeprazole の用量検索二重盲検試験. 薬理と治療 16 (suppl 3):S517-S541, 1988

• 5) 三好秋馬, 谷内昭, 後藤由夫ほか:Omeprazole の胃潰瘍に対する臨床的有用性の検討-多施設二重盲検法による Famotidine との比較-. 薬理と治療 16 (suppl 3):S543-S561, 1988

• 6) 竹本忠良, 並木正義, 後藤由夫ほか:胃潰瘍, 十二指腸潰瘍に対する Lansoprazole (AG-1749) の臨床的有用性の検討-用量および投与時期の検討-. 臨成人病 21:995-1013, 1991

• 7) 竹本忠良, 並木正義, 後藤由夫ほか:胃潰瘍に対する Lansoprazole (AG-1749) の臨床的有用性の検討-多施設二重盲検法によるFamotidine との比較-. 臨成人病 21:327-345, 1991

• 8) 中澤三郎, 並木正義, 松尾裕ほか:E3810の胃潰瘍, 十二指腸潰瘍に対する後期臨床第II相試験-二重盲検比較試験による至適用量の検討-. Mod Physician 14:38-68, 1994

• 9) 小田嶋傑, 大高道郎, 渡辺純夫:PPI 抵抗性の難治性潰瘍. 今月の治療 12:103-105, 2004

• 10) 上村直実:PPIとH2プロッカー. 医のあゆみ 210:470-474, 2004

P.123 掲載の参考文献

• 1) Borody TJ, George LL, Brandl S et al:Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 86:1154-1157, 1991
  pubmed

• 2) Nishikawa K, Sugiyama T Kato M et al:Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur l Gastroenterol Hepatol 12:635-640, 2000

• 3) van der Hulst RW Rauws EA, Koycu B et al:Prevention of ulcer reccurrence after eradication of Helicobacter pylori:aprospective long-term follow-up study Gastroenterol 113:1082-1086, 1997

• 4) Miwa H, Sakaki N, Sugano K et al:Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication:Amulticenter study of 4940 patients. Helicobacter 9:9-16, 2004

• 5) Ge ZZ, Zhang DZ, Xiao SD et al:Does eradication of Helicobacter pylori alone heal duodenal ulcers?Aliment Pharmacol Ther 14:53-58, 2000
  pubmed

• 6) Colin R:Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment:amulticentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 16:1157-1162, 2002
  pubmed

• 7) Gisbert JB Majares JM:Can peptic ulcer be healed with 7-day proton pump inhibitor based triple therapy? Aliment Pharmacol Ther 21:795-804, 2005

• 8) Yeomans ND, Tulassay Z, Juhasz L et al:Acomparison of omeprazole with ranitidine for ulcers associated with non-steroidal antiinflammatory drugs. N Engl J Med 338:719-726, 1998

• 9) Hawkey CJ, Karrasch JA, Szczepanski L et al:Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. 2V Engl J Med 338:727-734, 1998

P.129 掲載の参考文献

• 1) EBM に基づく胃潰瘍診療ガイドライン:科学的根拠 (evidence) に基づく胃潰瘍診療ガイドラインの策定に関する研究班編, じほう, 東京, 2003

• 2) 塩川優一, 斎藤輝信, 浅木茂ほか:非ステロイド性抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ 31:96-111, 1991

• 3) 久保田潔, 寺野彰, 菅野健太郎ほか:NSAID と H. Pylori 感染の上部消化管出血に対するリスクに関する一般住民ベースのケース・コントロール研究. 第91回日本消化器病学会総会シンポジウム:S7-S0I, 2005

• 4) Yeomans ND, Swannell AJ, Hawkey CJ et al:Acomparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial:Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719-726, 1998

• 5) Hawkey CJ, Swannell AJ, Yeomans ND et al:Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727-734, 1998

• 6) Bianchi Porro G, Montrone E Caruso I et al:Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study. Ital J Gastroenterol Hepatol 30:43-47, 1998

• 7) Taha AS, Sturrock RD, Russell RI et al:Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334:1435-1439, 1996
  pubmed

• 8) Hawkey CJ, Peacock RA, Gillon KR et al:Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs:HELP NSAIDs study Helicobacter Eradication for Lesion Prevention. Lancet 352:1016-1021, 1998
  pubmed

• 9) Chan FK, Chan HL, Sung JJ et al:Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Eng J Med 344:967-973, 2001
  pubmed

• 10) Vergara M, Gisbert Jp, Calvet X:Meta-analysis:role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21 (review):1411-1418, 2005
  pubmed

• 11) Lai KC, Lai CL, WOng J et al:Lansoprazole for the prevention of recurrences of ulcer complications ffom long-term low-dose aspirin use. N Engl J Med 346:2033-2038, 2002

P.137 掲載の参考文献

• 1) 川井啓市, 赤坂裕三, 木本邦彦ほか:急性胃病変の臨床-胃出血の面から. 胃と腸 8:17-23, 1973

• 2) 三好秋馬, 青木照明, 松尾裕ほか:上部消化管出血に対する Omeprazole 注射剤の臨床的研究. 薬理と治療 23:s2125-s2135, 1995

• 3) 三好秋馬, 青木照明, 中島光好ほか:上部消化管出血に対する Omeprazole 注射剤の臨床的研究. Famotidine 注射剤を対照薬とした二重盲検比較試験. 薬理と治療 23:s2125-s2135, 1995

• 4) 森瀬公友, 鈴木孝, 岡勇二ほか:上部消化管出血に対する Omeprazole 注射剤の止血効果および Omeprazole 経口剤の止血維持効果の検討. 薬理と治療 23:s2177-s2188, 1995

• 5) Levy MJ, Seelig CB, Robinson NJ et al:Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 42:1255-1259, 1997
  pubmed

• 6) Lasky MR, Metzler MH, Phillips JO:Aprospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 44:527-533, 1998

• 7) Topaloglu U, Muftuoglu T Akturk Z et al:Omeprazole is more effective than famotidine for preventing acute gastritis in rats. Surg Today 34:690-694, 2004
  pubmed

• 8) Nomura H, Miyake K, Kashiwagi S et al:Ashort-term eradication therapy for Helicobacter Pylori acute gastritis. J Gastroenterol Hepatol 15:1377-1381, 2000

• 9) Ohara S, Murayama N, Kuwata H et al:Effects of omeprazole on rat gastric mucus glycoproteins with acetylsalicylic acid-induced gastric damage. Arch Int Pharmacodyn Ther 296:192-201, 1988
  pubmed

• 10) Blandizzi C, Natale G, Gherardi G et al:Gastroprotective effects of pantoprazole against experimental mucosal damage. Fundam Clin Pharmacol 14:89-99, 2000
  pubmed

• 11) Kobayashi T, Ohta Y, Inui K et al:Protective effect of omeprazole against acute gastric mucosal lesions induced by compound 48/80, a mast cell degranulator in rats. Pharmacol Res 46:75-84, 2002
  pubmed

P.144 掲載の参考文献

• 1) 城卓志, 伊藤誠:上部消化管出血におけるプロトンポンプ阻害薬の適応とその根拠. プロトンポンプ阻害薬のすべて, 浅香正博, 千葉勉, 先端医学社, 東京, 2005, pp.129-133

• 2) Green FW Jr, Kaplan MM, Curtis LE et al:Effect of acid and pepsin on blood coagulation and platelet aggregation. Gastroenterology 74:38-43, 1978
  pubmed

• 3) Berstad A:Management of acute upper gastrointestinal bleeding. Scand J Gastroenterol 17:103-108, 1982

• 4) 三好秋馬, 青木照明, 中島光好ほか:上部消化管出血に対する Omeprazole 注射剤の臨床的研究-Famotidine 注射を対照薬とした二重盲検比較試験-. 薬理と治療 23 (suppl 8):S1593-S1608, 1995

• 5) Abe Y, Inamori M, Togawa J et al:The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. J Gastroenterol 39:21-25, 2004
  pubmed

• 6) Kinoshita Y:Editorial, Is an intravenous histamine H2 receptor anatagonist superior to an intravenous proton pump inhibitor in acid suppression? J Gastroenterol 39:92-93, 2004

• 7) 鎌田武信, 杉山貢, 竹本忠良ほか:上部消化管出血に対する lansoprazole (AG-1749)注射剤の第III相試験-famotidine 注射剤を対照薬とした二重盲検比較試験-. 臨床成人病 12:1813-1833, 1996

• 8) Lin HJ, Lo WC, Lee FY et al:A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 158:54-58, 1998
  pubmed

• 9) 大政良二, 浅木茂, 熊井浩一郎:内視鏡止血ガイドライン. 消化器内視鏡ガイドライン第1版, 日本消化器内視鏡学会監修, 医学書院, 東京, 1999, pp.170-181

• 10) 山内宏哲, 井口秀人, 松本恒司ほか:胃潰瘍入院クリニカルパスの有用性について. 日消誌 100:844-851, 2003
  Medical*Online

• 11) 小田島慎也, 矢作直久, 藤城光弘ほか:出血性消化性潰瘍に対するオメプラゾールの使用経験-注射剤から経口剤へのスイッチ療法-. Prog Med 24:206-211, 2004

P.151 掲載の参考文献

• 1) Zollinger RM, Ellison EH:Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 142:709-728, 1955
  pubmed

• 2) Polak JM, Stagg B, Pearse AGE:Two types of Zollinger-Ellison syndrome:immuno-fluorescent, cytochemical and ultrastructual studies of the antral and pancreatic gastrin cells in different clinical states. Gut 13:501-512, 1972

• 3) Ellison EC, Sparks J:Zollinger-Ellison syndrome in the era of effective acid suppression:are we unknowingly growing tumors? Am J Surg 186:245-248, 2003
  pubmed

• 4) Delvalle J, Yamada T:Zollinger-Ellison syndrome. In:Textook of Gastroenterology, ed. by Yamada T, JB Lippincott, Philadelphia, 1995, p. 1430

• 5) Nobels FR, Kwekkeboom DJ, Coopmans W et al:Chromogranin A as serum marker for neuroendocrine neoplasia:comparison with neuron-specific enolase and the α-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82:2622-2628, 1997

• 6) Gibril E Reynolds JC, Doppman JL et al:Somatostatin receptor scintigraphy:its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125:26-34, 1996

• 7) Metz DC, Pisegna JR, Fishbeyn VA et al:Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 17:468-480, 1993
  pubmed

• 8) Maton PN, Vinayek R, Frucht H et al:Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome:aprospective study Gastroenterology 97:827-836, 1989

P.160 掲載の参考文献

• 1) 濱中久尚, 後藤田卓志, 横井千寿ほか:早期胃癌に対する切開・剥離法の治療成績と問題点. ITナイフ. 胃と腸 39:27-34, 2004

• 2) 井手博子, 江口礼紀, 中村努ほか:食道癌切除再検術後の病態の検討. 日消外会誌 28:2057-2061, 1995

• 3) 宮崎信一, 神津照雄, 菱川悦男ほか:胃管再建と逆流性食道炎. 消化器内視鏡 10:59-63, 1998

PART6. 胃食道逆流症治療におけるプロトンポンプ阻害薬の臨床的意義を探る

P.168 掲載の参考文献

• 1) GERD ガイドラインワークショップレポート 2002, GERD研究会発行, 2002

• 2) 0kamoto K, Iwakiri R, Mori M et al:Clinical symptoms in endoscopic reflux esophagitis:evaluation in 8031 adult subjects. Dig Dis Sci 48:2237-2241, 2003

• 3) 大原秀一, 神津照雄, 河野辰幸ほか:全国調査における日本人の胸やけ・逆流性食道炎に関する疫学的検討. 日消誌 102:1010-1024, 2005

• 4) Dimenas E:Methodological aspect of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 28 (suppl 199):s18-s21, 1993

• 5) Ware JE, Sherbourne CD:The MOS 36-item short form healthy survey (SF-36). Med Care 30:473-481, 1992

• 6) Svedlund J, Sjodin I Dotevall G:GSRS-a clinical rating scale for gastrointestinal symptoms and in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33:129-134, 1988
  pubmed

• 7) Duppy HJ:The Psychological Well-Being (PGWB) Index. Assessment of Quality of Life in Clinical trails of Cardiovascular Therapies, eds. by Wengeron NK, Mattson ME, Furberg CF et al, Le Jacq Publishing, USA, 1984, pp. 170-184

• 8) Carlsson R, Dent J, Bolling-Sternvald E et al:The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 33:1023-1029, 1998

• 9) 永野公一, 久保光彦, 近藤守孝ほか:GERD の診断に関する研究. 新薬と臨 47:841-851, 1998

• 10) Velanovich V, Vallance SR, Gusz JR et al:Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 183:217-224, 1996
  pubmed

• 11) Kusano M, Shimoyama Y, Sugimoto S et al:Development and evaluation of FSSG:frequency scale for symptoms of GERD. J Gastoroenterol 39:888-891, 2004
  pubmed

• 12) DeVaault KR, Castell DO:Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroeterol 100:190-200, 2005

• 13) Havelund T, Lind T, Wiklund I, Glise H et al:Quality of life in patients with heartburn but without esophagitis:effects of treatment with Omeprazole. Am J Gastroeterol 94:1723-1724, 1999

• 14) Revicki DA, Sorenson S, Maton PN et al:Health related quality of life outcomes ofomeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 16:284-291, 1998

• 15) Lauritsen K:Management of Endoscopy-negative reflux disease:progress with short-term treatment. Aliment Pharmacol Ther 11 (suppl 2):s87-s92, 1997

• 16) Johanson JE Siddique R, Damiano AM et al:Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci 47:2574-2578, 2002

• 17) 0da K, Iwakiri l, Hara M et al:Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci 50:1921-1926, 2005

P.178 掲載の参考文献

• 1) Komazawa Y, Adachi K, Mihara T et al:Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol 18:678-682, 2003
  pubmed

• 2) Fujisawa T, Adachi K, Komazawa Y et al:Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists. Aliment Pharmacol Ther 20:559-565, 2004
  pubmed

• 3) Katsube T, Adachi K, Kawamura A et al:Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049-1056, 2000
  pubmed

• 4) Vakil N:Review article:new pharmacological agents for the treatment of gastro-oesophageal refiux disease. Aliment Pharmacol Ther 19:1041-1049, 2004

• 5) Adachi K, Fujishiro H, Katsube T et al:Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16:1191-1196, 2001

• 6) Fujishiro H, Adachi K, Kawamura A et al:Influence of Helicobacter pylori infection on the prevalence of reflux esophagitis in Japanese patients. J Gastroenterol. Hepatol 16:1217-1221, 2001
  pubmed

• 7) Adachi K, Komazawa Y, Fujishiro H etal:Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects:effects of different regimens. J Gastroenterol 38:830-835, 2003
  pubmed

• 8) Adachi K, Komazawa Y, Mihara T et al:Administration of H2 receptor antagonist with proton pump inhibitor is effective for long-term control of refractory reflux esophagitis. J Clin Gastroenterol 38:297-298, 2004
  pubmed

P.187 掲載の参考文献

• 1) Hongo M, Shoji T:Epidemiology of reflux disease and CLE in East Asia. J Gastroenterol 38:25-30, 2003
  pubmed

• 2) Wuesten BI, Roelofs JM, Akkermans LM et al:The symptom-association probability:an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 107:1741-1745, 1994

• 3) GERD 研究会:GERD ガイドラインワークショップレポート2002, エム・シー・アンド・ピー, 大阪, 2002

• 4) 本郷道夫, 田村太作:非びらん性胃食道逆流症. 日本臨牀 62:1565-1569, 2004
  Medical*Online

• 5) Hongo M, Kanatsuka H, Sugawara A et al:Primary care in the treatment of functional gastrointestinal symptoms in Japan:prescription preferences and impression of results. Aliment Pharmacol Ther 21:47-54, 2005
  pubmed

P.198 掲載の参考文献

• 1) GERD ガイドラインワークショップレポート 2002, GERD 研究会発行, 2002

• 2) 本郷道夫:GERDに対する薬物療法-GERD の治療とガイドライン-. 消内視鏡 15:1685-1699, 2003

• 3) 羽生泰樹:GERD の薬物治療. 消臨 8:311-317, 2005

• 4) 天野和寿, 木下芳一:VI. 胃食道逆流症の治療2. 薬物療法. 日内会誌 89:68-73, 2000

• 5) Chiba N, De Gara CJ, Wilkinson JM et al:Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease:ameta-analysis. Gastroenterology 112:1798-1810, 1997

• 6) DeVault KR, Castell DO:Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100:190-200, 2005
  pubmed

• 7) Dekkers CP, Beker JA, Thjodleifsson B et al:Double-blind comparison[correction of Double-blind, placebo-controlled comparison]of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 13:49-57, 1999

• 8) Katzka DA, Paoletti V, Leite L et al:Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms:testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol 96:2110-2113, 1996

• 9) Peghini PL, Katz PO. Bracy NA et al:Nocturnal recovery of gastric acid secretion with ice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763-767, 1998

• 10) Katz PO, Anderson C, Khoury R et al:Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 12:1231-1234, 1998
  pubmed

• 11) Katsube T, Adachi K, Kawamura A et al:Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment pharmacol Ther 14:1049-1056, 2000
  pubmed

• 12) Peghini PL, Katz PO, Castell DO:Ranitidine controls nocturnal gastric acid breakthrough on omeprazole:acontrolled study in normal subjects. Gastroenterology 115:1335-1339, 1998

• 13) Horai Y, Nakano M, Ishizaki T et al:Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects:Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198-207, 1989
  pubmed

• 14) Ishizaki T, Horai Y:Cytochrome P 450 and the metabolizer of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 (suppl 3) 27-36, 1999

• 15) Furuta T, Ohashi K, Kamata T et al:Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129:1027-1030, 1998
  pubmed

• 16) Furuta T, Ohashi K, Kosuge K et al:CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552-561, 1999
  pubmed

• 17) Adachi K, Katsube T, Kawamura A et al:CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 14:1259-1266, 2000
  pubmed

• 18) Kawamura M, Ohara S, Koike T et al:The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 17:965-973, 2003
  pubmed

• 19) Ahizumi K, Ohara S, Koike T et al:The therapeutic effects of rabeprazole at a dose of 10mg on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J Gastroenterol Hepatol (in press)

• 20) Ohkusa T, Maekawa T, Arakawa T et al:Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients With recurrent renux oseophagitis. Aliment Pharmacol Ther 21:1332-1339, 2005

• 21) Martinek J, Kuzela L, Spicak A et al:Review article:the clinical influence of Helicobacter pylori in effective acid suppression-implications fbr the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:979-990, 2000

• 22) Verdu EE Armstrong D, Fraser R et al:Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 36:539-543, 1995

• 23) Gillen D, Wirz AA, Neithercut WD et al:Helicobacter pylori infection potentiates the irlhibition of gastric acid secretion by omeprazole. Gut 44:468-475, 1999
  pubmed

• 24) Verdu EE Armstrong D, Idstrom Jp et al:Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 37:743-748, 1995

• 25) Schenk BE, Kuipers EJ, Klinkenberg-Knol EC et al:Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 94:884-887, 1999
  pubmed

• 26) Talley NJ, Meineche-Schmidt V, Pare P et al:Efficacy of omeprazole in functional dyspepsia:double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 12:1055-1065, 1998
  pubmed

• 27) Holtmann G, Cain C, Malfertheiner P:Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 117:11-16, 1999
  pubmed

• 28) 小池智幸, 大原秀一, 関根仁ほか:逆流性食道炎のプロトンポンプ阻害薬に対する Helicobacter Pylori 感染の関与. プロトンポンプ阻害薬のすべて, 浅香正博, 千葉勉編, 先端医学社, 東京, 2002, pp.174-178

• 29) Bell NJ, Hunt RH:Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 33:118-124, 1992
  pubmed

• 30) Vigneri S, Termini R, Leandro G et al:Acomparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333:1106-1110, 1995

• 31) Fennerty MB, Castell D, Fendric AM et al:The diagnosis and treatment of gastroesophageal reflux disease in a managed care enviroment, suggested disease managements guidelines. Arch Intern Med 156:477-484, 1990

• 32) 関口利和, 遠藤光夫, 本郷道夫ほか:H2受容体拮抗薬抵抗性逆流性食道炎に対する Omeprazole の臨床評価 (第2報)-再発予防効果と安全性の検討-. 臨医薬 16:1387-1404, 2000

• 33) 羽生泰樹, 池浦司, 浦井俊二ほか:コストベネフィットからみた GERD 治療におけるプロトンポンプ阻害薬の有用性. プロトンポンプ阻害薬のすべて, 浅香正博, 千葉勉編, 先端医学社, 東京, 2002, pp.153-158

• 34) Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al:Atrophic gastritis and Helicobacter pylori infection in patients with refiux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334:1018-1022, 1996
  pubmed

• 35) Lundell L, Miettinen P, Myrvold HE et al:Lack of effect of acid suppression therapy on gastric atrophy Gastroenterology 117:319-326, 1999

• 36) 上村直実:PPI長期投与の問題点 (2) 胃炎の進展と胃粘膜萎縮に及ぼす影響, 臨消内科 17:217-222, 2002

• 37) Lundell LR, Dent J, Bennett JR et al:Endoscopic assessment of oesophagiatis:clinical and functional correlates and further validation of the Los Angeles classification. Gut 45:172-180, 1999

• 38) 樋口達也, 草野元康:内視鏡経過観察の実際. 消臨 8:306-309, 2005

• 39) 小池智幸, 大原秀一, 猪股芳文ほか:Barrett 食道/癌の病態および内視鏡的特徴と治療. 消化器科 41:29-34, 2005

• 40) 星原芳雄:内視鏡による診断. 日臨 62:1459-1464, 2004

• 41) Carlsson R, Dent J, Bolling-Stervald E et al:The usefulness of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 33:1023-1029, 1998

• 42) 永野公一, 久保光彦, 後藤守孝ほか:GERD の診断に関する研究-上部消化管症状を訴える患者におけるアンケート (QUEST) による検討-. 新薬と臨 47:841-851, 1998

• 43) Kusano M, Shimoyama Y, Sugimoto S et al:Development and evaluation of FSSG:frequency scale for the symptoms of GERD. J Gastroenterology 39:888-891, 2004

• 44) 草野元康, 下山康之, 杉本さやかほか:GERD に対する新しい問診票FSSG (Fre-quency Scale for the Symptoms of GERD 通称:F スケール) の開発と評価. 臨床と研究 82:379-382, 2004

• 45) Sampliner RE:The practice parameters committee of the American college of gastroenterology:Updated guidelines for the diagnosis, surveillance, and therapy of Barrett:s esophagus. Am J Gastroenterol 97:1888-1896, 2002
  pubmed

• 46) Conio M, Blanchi S, Laperatosa G et al:Lomg-tem endoscopic surveillance of patients with Barrett:s esophagus. Incidence of dysplasia and adenocarcinoma:Aprospective study. Am J Gastroenterol 98:1931-1939, 2003

PART7. Helicobacter pylori除菌治療におけるプロトンポンプ阻害薬の臨床的意義を探る

P.212 掲載の参考文献

• 1) Warren JR, Marshall B:Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i:1273-1275, 1983
  pubmed

• 2) NIH consensus development panel on Helicobacter pylori in peptic ulcer disease Helicobacter Pylori in peptic ulcer disease. JAMA 272:65-69, 1994

• 3) 日本消化器病学会 Helicobacter pylori 治験検討委員会:Helicobacter pylori 治験ガイドライン資料, 竹本忠良編, 1995

• 4) 日本ヘリコバクター学会ガイドライン作成委員会:Helicobacter Pylori 感染の診断と治療のガイドライン. 日本ヘリコバクター学会誌 2 (suppl):S1-S12, 2000

• 5) 日本ヘリコバクター学会ガイドライン作成委員会:Helicobacter Pylori 感染の診断と治療のガイドライン2003年改訂版. Helicobacter Res 7:253-265, 2003
  Medical*Online

• 6) 佐々木徹, 西元寺克禮, 樋口勝彦ほか:H. Pylori の感染経路と疫学. Surg Fronti 11:112-117, 2004
  Medical*Online

• 7) 藤岡利生, 香川二朗, 児玉雅明:Helicobacter Pylori 除菌療法の補助薬としてのプロトンポンプ阻害薬の意義. プロトンポンプ阻害薬のすべて, 浅香正博, 千葉勉編, 先端医学社, 東京, 2002, pp.180-184

• 8) Tytgat GNJ, Axon ATR, Dixon MF et al:Helicobacter pylori:casual agent in peptic ulcer disease?In:Working Party Reports of the VVorld Congress of Gastroen terology, Blackwell Scientific Publications, Melbourne, 1990, pp. 36-45

• 9) 佐藤貴一, 木平健, 瀧本拓哉ほか:Helicobacter pylori 除菌の世界の現状. Helicobacter Res 1:24-30, 1997
  Medical*Online

• 10) Bazzoli E Zagari M, Fossi S et al:Efficacy and tolerability of a short term, low dose triple therapy for eradication of Helicobacter pylori. Gastroenterology 104:A40 (abstract), 1993

• 11) M?graud F, Malfertheiner P:Treatment of Helicobacter pylori infection:summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995. Helicobacter 1:118-121, 1996

• 12) Fujioka H, Ohkura R, Murai T et al:In vitro activity of novel proton pump inhibitors against Helicobacter pylori. In:Recent Advances in Chemotherapy eds. by Einhorn J et al, ASM, Washington DC, 1995, pp. 612-613

• 13) 林千鶴子, 坂上隆, 三輪洋人:除菌治療効果とPPI・H2RAの使い分け. 臨消内科 20:1193-1200, 2005

• 14) Sachs G, Shin JM, Munson K et al:Review article:the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther 14:1383-1401, 2000
  pubmed

• 15) Gustavson LE, Kaiser JE Edmonds AL et al:Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 39:2078-2083, 1994

• 16) Ell C, Schoerner C, Solbach W et al:The AMOR study:arandomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 13:685-691, 2001

• 17) Hu FL, Jia JC, Li YL et al:Comparison of H2-receptor antagonist-and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcen. J Int Med Res 31:469-474, 2003
  pubmed

• 18) Lind T, Veldhuyzen van Zanten S, Unge P et al:Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials:the MACH I Study. Helicobacter 1:138-144, 1996

• 19) Lind T, Megraud E Unge P et al:The MACH2 study:role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253, 1999

• 20) Malfertheiner P, Bayerdorffer E, Diete U et al:The GU-MACH study:the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 13:703-712, 1999

• 21) Zanten SJ, Bradette M, Farley A et al:The DU-MACH study:eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 13:289-295, 1999
  pubmed

• 22) Asaka M, Sugiyama T, Kato M et al:A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter Pylori in Japanese peptic ulcer patients. Helicobacter 6:254-261, 2001

• 23) 桑山肇, 吉田俊一, 中村武史ほか:オメプラゾール, アモキシシリン, およびクラリスロマイシンの3剤併用による Helicobacter pylori 除菌療法の第III相二重盲検比較試験. 第7回日本ヘリコバクター学会抄録集, 2001, p.155

• 24) Miwa H, Ohkura R, Murai T et al:Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 13:741-746, 1999
  pubmed

P.223 掲載の参考文献

• 1) NIH consensus:Helicobacter pylori in peptic ulcer disease. JAMA 272:65-69, 1994

• 2) International agency for research on cancer, World Health Organization:Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risk Hum. 61:177-241, 1994

• 3) The European Helicobacter pylori Study Group:Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41:8-13, 1997

• 4) American Digestive Health Foundation:The report of the digestive health initiative inteernational update conference on Helicobacter pylori. Washington DC, 1997

• 5) Lam SK, Talley NJ:Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13:1-12, 1998

• 6) Rubin GP Meineche-Schmidt V Roberts AP et al:The use of consensus to develop guidelines for the management of Helicobacter pylori infection in primary care. Family Practice 17:S17-S26, 2000

• 7) Malfertheiner P, Megraud E O:Morain C et al:Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16:167-180, 2002

• 8) Sherman P, Hassall E, Hunt RH et al:Canadian Helicobacter study group consensus conference on the approach to Helicobacter pylori infection in children and adolescents. Can J Gastroenterol 13:553-559, 1999

• 9) Drumm B, Koletzko S, Oderda G:Helicobacter pylori infection in children:aconsensus statement. J Pediatr Gastroenterol Nutr 30:207-213, 2000

• 10) Helicobacter Pylori 治験検討委員会:Helicobacter pylori 治験ガイドライン, 1995

• 11) Helicobacter Pylori 治験検討委員会:Helicobacter Pylori 治験ガイドライン. 日消誌 96:199-207, 1999
  Medical*Online

• 12) 日本ヘリコバクター学会ガイドライン作成委員会:H. Pylori感染の診断と治療のガイドライン. 日本ヘリコバクター学会誌 2 (suppl):S1-S12, 2000

• 13) Asaka M, Satoh K, Sugano K et al:Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 6:177-186, 2001
  pubmed

• 14) 日本ヘリコバクター学会ガイドライン作成委員会:H. pylori 感染の診断と治療のガイドライン2003年改訂版. 日本ヘリコバクター学会誌 4 (suppl):2-16, 2003
  Medical*Online

• 15) 加藤晴一, 小林昭夫, 杉山敏郎ほか:小児の Helicobacter pylori 除菌療法に関するガイドライン (案) の提唱. 日本小児栄養消化器病学会誌 11:173-176, 1997

• 16) 加藤晴一, 今野武津子, 豊田茂ほか:第27回日本小児栄養消化器病学会, 講演抄録集, p52, 2000

• 17) Asaka M, Sugiyama T, Kato M et al:A multicenter, double-blind study on triple therapy with lansoprazole, amoxicilin, and clarithromycin for eradication of Helicobacter Pylori in Japanese peptic ulcer patients. Helicobacter 6:254-261, 2001

• 18) Kato M, Yamaoka Y, Kim JJ et al:Regional Differences in Metronidazole Resistance and Increasing Clarithromycin Resistance among Helicobacter pylori Isolates from Japan. Antimicrob Agents Chemother 44:2214-2216, 2000
  pubmed

• 19) Perez Aldana L, Kato M, Nakagawa S et al:The Relationship between Consumption of Antimicrobial Agents and the Prevalence of Primary Helicobacter pylori Resistance. Helicobacter 7:306-309, 2002
  pubmed

P.233 掲載の参考文献

• 1) 医学通信社編集部編:DPC 点数早見表 (04年4月版/05年4月補訂), 医学通信社, 東京, 2005

• 2) Miwa H, Sakaki N, Sugano K et al:Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication:amulticenter study of 4940 patients. Helicobacter 9:9-16, 2004

• 3) EBM に基づく胃潰瘍診療ガイドライン:科学的根拠 (evidence) に基づく胃潰瘍診療ガイドラインの策定に関する研究班編, じほう, 東京, 2003

• 4) Habu Y, Inokuchi H, Kiyota K et al:Economic evaluation of Helicobacter pylori eradication for the treatment of duodenal ulcer disease in Japan:adecision analysis to assess eradication strategy. J Gastroenterol Hepatol 13:280-287, 1998

• 5) 大原秀一, 下瀬川徹:Helicobacter Pylori 除菌治療の医療経済効果. Helicobacter Res 4:238-242, 2000
  Medical*Online

• 6) 池田俊也, 圭室俊雄, 浅香正博:Helicobacter Pylori 除菌3剤併用療法の薬剤経済学的分析. Helicobacter Res 4:563-567, 2000
  Medical*Online

• 7) Uemura N, Mukai T, Okamoto S et al:Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarleers」Prev 6:639-642, 1997

• 8) Shimizu N, Ikehara Y, Inada K et al:Eradication diminishes enhancing effects of Helicobacter pylori infection glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 60:1512-1514, 2000
  pubmed

• 9) Wong BC, Lam SK, Wong WM et al:Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China:arandomized controlled trial. JAMA 291:187-194, 2004

• 10) Take S, Mizuno M, Ishiki K et al:The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 100:1037-1042, 2005
  pubmed

P.242 掲載の参考文献

• 1) 日本ヘリコバクター学会ガイドライン作成委員会:Helicobacter Pylori 感染の診断と治療のガイドライン. 日本ヘリコバクター学会誌 2 (suppl):S2-S12, 2000

• 2) EBM に基づく胃潰瘍診療ガイドライン:科学的根拠 (evidence) に基づく胃潰瘍診療ガイドライン策定に関する研究班編, じほう, 東京, 2003

• 3) Asaka M, Kato M, Sugiyama T et al:Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 38:339-347, 2003
  pubmed

• 4) 高橋信一:これでわかるピロリ除菌療法と保険適用-ガイドラインに基づく活用法-, 南江堂, 東京, 2001

P.250 掲載の参考文献

• 1) Marshall BJ, Warren JR:Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet i:1311-1315, 1984
  pubmed

• 2) Labenz J, Blum AL, Bayerdorffer E et al:Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112:1442-1447, 199

• 3) Fallone CA, Barkun AN, Friedman G et al:Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 95:914-920, 2000
  pubmed

• 4) Befrits R, Sjostedt S, Odman B et al:Curing Helicobacter Pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter 5:202-205, 2000

• 5) Rokkas T, Ladas SD, Liatsos C et al:Effectiveness of acid suppression in preventing gastroesophageal reflux disease (GERD) after successful treatment of Helicobacter pylori infection. Dig Dis Sci 46:1567-1572, 2001
  pubmed

• 6) Bytzer R Aalykke C, Rune S et al:Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group. Scand J Gastroenterol 35:1023-1032, 2000

• 7) McColl KE:Motion--Helicobacter pylori causes or worsens GERD:arguments against the motion. Can J Gastroenterol 16:615-617, 2002
  pubmed

• 8) Hosking SW Ling TK, Chung SC et al:Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment:randomised controlled trial, Lancet 343:508-510, 1994
  pubmed

• 9) Liu CC, Lee CL, Chan CC et al:Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding Peptic ulcer:a 5-year prospective, randomized, controlled study. Arch Intern Med 163:2020-2024, 200
  pubmed

• 10) Miwa H, Sakaki N, Sugano K et al:Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication:amulticenter study of 4940 patients. Helicobacter 9:9-16, 2004

• 11) Huang JQ, Sridhar S, Hunt RH:Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease:ameta-analysis. Lancet 359:14-22,

• 12) Wong WM, Wong BC, Wong KW et al:13C-urea breath test without a test meal is highly accurate for the detection of Helicobacter pylori infection in Chinese. Aliment Pharmacol Ther 14:1353-1358, 2000

• 13) Laine L, Estrada R, Trujillo M et al:Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Interna Med 129:547-550, 1998

• 14) Borody TJ, Andrews B Mancuso N et al:Helicobacter pylori reinfection rate, in patients with cured duodenal ulcer. Am J Gastroenterol 89:529-532, 1994

• 15) Vergara M, Catalan M, Gisbert Jp et al:Meta-analysis:role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 21:1411-1418, 2005
  pubmed

• 16) Ohara T, Morishita T, Suzuki H et al:Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori:pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI. Hepatogastroenterology 51:338-342, 2004

• 17) Solvell L:The clinical safety of omeprazole. Digestion 47 (suppl 1):S59-S63, 1990

P.258 掲載の参考文献

• 1) Asaka M, Kato M, Sugiyama T et al:Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with Iansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 38:339-347, 2003

• 2) Graham DY, Lew GM, Malaty HM et al:Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102:493-496, 1992
  pubmed

• 3) Wermeille J, Dederding Jp, Cunningham M et al:Failure of Helicobacter Pylori eradication in an ambulatory population:is poor compliance the main cause?Digestion 59 (suppl 3):s437, 1998

• 4) 古田隆久:H. pylori 除菌治療と PPI:CYP2C19 の遺伝的多型性との関連より-. 藤岡利生, 榊信廣編:ヘリコバクター・ピロリフォーラム-病態と治療の最前線医学書院, 東京, 1999, pp.110-117

• 5) Alarcon T, Domingo D, Lopez-Brea M:Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 12:19-26, 1999

• 6) 日本化学療法学会 抗菌薬感受性測定委員会:ヘリコバクターピロリ委員会:Helicobacter pylori 除菌療法における clarithromycin (CAM) および amoxicillin (AMPC) のブレイクポイント制定に関する報告書. 日化療会誌 48:561-567, 2000

• 7) Murakami K, Fujioka T, Okimoto T et al:Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 19:67-70, 2002

• 8) Kato M, Yamaoka Y, Kim JJ et al:Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Anti-microb Agents Chemother 44:2214-2216, 2000

• 9) 村上和成, 佐藤竜吾, 藤岡利生ほか:特集 胃・十二指腸潰瘍-基礎・臨床の最新傾向-二次除菌療法. 日臨 62:489-494, 2004

• 10) Murakami K, Sato R, Okimoto T et al:Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 16:1933-1938, 2002

• 11) 村上和成, 加藤元嗣, 加藤晴一ほか:わが国における薬剤耐性 Helicobacter Pylori の現状-平成14年度耐性菌サーベイランスの集計報告-. 日本ヘリコバクター学会誌 6:42-47, 2004
  Medical*Online

• 12) 日本ヘリコバクター学会ガイドライン作成委員会 H. pylori 感染の診断と治療のガイドライン. 日本ヘリコバクター学会誌 4 (suppl):s2-s17, 2003

• 13) Nagahara A, Miwa H, Ohkura R et al:Strategy for retreatment of therapeutic failure of eradication of Helicobacter Pylori infection. J Gastroenterol Hepatol 115:613-618, 2001

• 14) Murakami K, Sato R, Okimoto T et al:Efficacy of triple therapy comprising rabeprazole, amoxicillin, and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 17:119-123, 2003
  pubmed

• 15) Nagahara A, Miwa H, Kawabe M et al:Second-line treatment for Helicobacter pylori infection in Japan:proton pump inhibitor-based amoxicillin and metronidazole regimen. J Gastroenterol 39:1051-1055, 2004

• 16) Shimoyama T, Fukuda S, Mikami T et al:Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J Gastroenterol 39:927-930, 2004

• 17) Megraud E Doermann HP:Clinical relevance of resistant strains of Helicobacter pylori:a review of current data. Gut 43:S61-S65, 1998

• 18) Beard RN, Noller KL, O:Fallon WM et al:Cancer after exposure to metronidazole. Mayo Clin Proc 63:147-153, 1988

• 19) Friedman GD, Selby JV:Metronidazole and cancer. JAMA 261:866, 1989
  pubmed

• 20) 山本達男, 種池郁恵, 合志聡ほか:メトロニダゾールについて (耐性・発癌性など). 日本ヘリコバクター学会誌 4:30-33, 2002
  Medical*Online

• 21) 白井直人, 古田隆久:H. pylori 除菌療法-高用量PPI/AMPC療法-. 日臨 60:439-444, 2002

• 22) Isomoto H, Inoue K, Furusu H et al:High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 18:101-107, 2003
  pubmed

• 23) Gisbert Jp, Boixeda D, Bermejo F et al:Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 11:1049-1054, 1999
  pubmed

• 24) Gomollon E Ducons JA, Ferrero M et al:Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy:a detailed, prospective analysis of 21 consecutive cases. Helicobacter 4:222-225, 1999
  pubmed

• 25) Lee JM, Breslin D, Hyde DK et al:Treatment opinions for Helicobacter pylori infection when proton pump infibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 13:489-496, 1999

• 26) Murakami K, Sato R, Okimoto T et al:Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 21:262-267, 2006
  pubmed

P.265 掲載の参考文献

• 1) 日本ヘリコバクター学会ガイドライン作成委員会:Helicobacter Pylori 感染の診断と治療のガイドライン改訂版. 日本ヘリコバクター学会誌 4 (suppl):s 2-s 16, 2003

• 2) Kato M, Hokari K, Kagaya H et al:Traditional and non-traditional antimicrobial agents for H. pylori infection. Curr Pharm Des 6:1575-1581, 2000
  pubmed

• 3) Nagata K, Satoh H, Iwahi T et al:Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori:unique action selective for H. pylori cells. Antimicrob Agents Chemother 37:769-774, 1993
  pubmed

• 4) Hirai M, Azuma T, lto S et al:A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 30:461-464, 1995

• 5) Chey WD, Spybrook M, Carpenter S et al:Prolonged effect of omeprazole on the 14C-urea breath test. Am J Gastroenterol 91:89-92, 1996
  pubmed

• 6) El-Nujumi A, Hilditch TE, Williams C et al:Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the 14C-urea breath test. Eur J Gastroenterol Hepatol 10:759-764, 1998
  pubmed

• 7) Laine L, Estrada R, Trujillo M et al:Effect of proton pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 129:547-550, 1998

• 8) Hamlet A, Stage L, Lonroth H et al:Anovel tablet-based 13C-urea breath test for Helicobacter pylori with enhanced performance during acid suppression therapy. Scand J Gastroenterol 34:367-374, 1999

• 9) Savarino V, Bisso G, Pivari M et al:Effect of gastric acid suppression on 13C-urea breath test:comparison of ranitidine with omeprazole. Aliment Pharmacol Ther 14:291-297, 2000
  pubmed

• 10) Parente E Sainaghi M, Sangaletti O et al:Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the 13C-urea breath test. Aliment Pharmacol Ther 16:553-557, 2002
  pubmed

• 11) Levine A, Shevah O, Shabat-Sehayek V et al:Masking of 13C-urea breath test by proton pump inhibitors is dependent on type of medication:comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Aliment Pharmacol Ther 20:117-122, 2004
  pubmed

• 12) Mana E Van Laere W, Bossuyt A et al:The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test. Dig Liver Dis 37:28-32, 2005

• 13) Gatta L, Vakil N, Ricci C et al:Effect of proton pump inhibitors and antacid therapy on 13C-urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 99:823-829, 2004

• 14) Adachi K, Fujishiro H, Mihara T et al:Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test fbr the diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol 18:168-171, 2003

• 15) Graham DY, Opekun AR, Jogi M et al:False negative urea breath tests with H2-receptor antagonists:interactions between Helicobacter pylori density and pH. Helicobacter 9:17-27, 2004
  pubmed

PART8. プロトンポンプ阻害薬の使い方と注意点

P.274 掲載の参考文献

• 1) Nikfar S, Abdollahi M, Moretti ME et al:Use of proton pump inhibitors during pregnancy and rates of major malformations:ameta-analysis. Dig Dis Sci 47:1526-1529, 2002

• 2) Gibbons TE, Gold BD:The use of proton pump inhibitors in children:a comprehensive review. Paediatr drugs 5:25-40, 2003
  pubmed

• 3) Horn J:Review article:relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. Aliment Pharmacol Ther 20 (suppl 6):s11-s 19, 2004

• 4) 岡崎和一:プロトンポンプ阻害薬の薬物間相互作用で知っておくべき知識は何か. プロトンポンプ阻害薬のすべて, 浅香正博, 千葉勉編, 先端医学社, 東京, 2002, pp.231-237

• 5) Freston JVV, Kukulka MJ, Lloyd E et al:Anovel option in proton pump inhibitor dosing:lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. Aliment Pharmacol Ther 20:407-411, 2004

• 6) Laine L, Ahnen D, McClain C et al:Review article:potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14:651-668, 2000
  pubmed

• 7) Rindi G, Fiocca R, Morocutti A et al:Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol 17:559-566, 2005

P.283 掲載の参考文献

• 1) Stedman CA, Barclay ML:Review article:comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963-978, 2000
  pubmed

• 2) Delhotal-Landes B, Cournot A et al:The effect of food and artacid on lansoprazole absorption and sisposition. Eur J Drg Metab Pharmacikinet 3:315, 1991

• 3) Humphries TJ:clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazple. Dig Dis Sci 36:1665-1669, 1991
  pubmed

• 4) 三輪清, 三谷政義, 塚本剛司 ほか:新規プロトンポンプ阻害剤 AG-1749 のラット, マウス, イヌにおける生体内動態. 薬理と治療 18:3413, 1990
  Medical*Online

• 5) 吉田隆久:H. pylori 除菌療法とPPI-CYP2C19 の遺伝子的多型との関連より-. ヘリコバクター・ピロリ・フォーラム 病態と治療の最前線, 藤岡利生, 榊信廣編, 医学書院, 東京, 2000, pp.110-117

• 6) Ishizaki T, Horai Y:Review article;cytochrome p450 and the mechanism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 (suppl 3):S 527-S536, 1999

• 7) 岡崎和一:プロトンポンプ阻害薬の薬物間相互作用で知っておくべき知識は何か, 浅香正博, 千葉勉編, プロトンポンプ阻害薬のすべて, 先端医学社, 東京, 2002, pp.231-233

• 8) Kokuhu T, Ihara N, Sugioka N et al:Effects of lansoprazole on pharmacokinetics and metabolisms of theophylline. Eur J Clin Pharmacol 48:391-395, 1995

P.290 掲載の参考文献

• 1) 羽生泰樹:日本における逆流性食道炎治療の費用効果分析:(1) PPI first strategy と step-up strategy, (II) 維持療法における PPI と H2RA の比較評価. Ther Res 22:1067-1071, 2001

• 2) 羽生泰樹, 吉野琢哉, 塩せいじほか:GERD の維持療法-PPIとH2RAの役割と領域-. 日臨 62:1504-1509, 2004
  Medical*Online

• 3) 羽生泰樹, 渡邊能行, 川井啓市:GERD 治療の医療経済. Medicina 42:22-24, 2005

• 4) 羽生泰樹:GERD ガイドラインステートメント治療5. GERD ガイドラインワークショップレポート2002, GERD研究会, 2002, p.54

• 5) 羽生泰樹:GERD ガイドラインステートメント治療6. GERD ガイドラインワークショップレポート2002, GERD研究会, 2002, p.55

• 6) 羽生泰樹:逆流性食道炎治療に関する実態調査-逆流性食道炎患者と医師へのアンケート調査から-. Prog Med 24:1133-1145, 2004
  Medical*Online

• 7) 佐藤信紘, 大草敏史, 三田地泰司ほか:再発・再燃を繰り返す逆流性食道炎患者へのオメプラゾール錠投与1ヵ月後の患者満足度の評価 患者自己記入式調査票による満足度調査. 薬理と治療 31:163-175, 2003

• 8) 関口利和:GERDの治療は (2) Step-up. 臨消内科 14:1583-1587, 1999